FDA approves ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Atrial fibrillation, the most common type of irregular heartbeat, affects approximately 5.8 million people in the U.S., and results in a five times greater risk of stroke.
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease
- Details
- Category: Novartis
Novartis announced that the US Food and Drug Administration (FDA) has approved Signifor® (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative3. Signifor is the first medicine to be approved in the US that addresses the underlying mechanism of Cushing's disease,
GSK forms partnership with Vodafone to help increase childhood vaccination in Mozambique
- Details
- Category: GlaxoSmithKline
GSK has formed a partnership with Vodafone to harness innovative mobile technology to help vaccinate more children against common infectious diseases in Africa. Despite major advances in the funding and availability of vaccines worldwide, it is estimated that up to a fifth of children worldwide still do not receive basic vaccines.
Roche reports positive studies of MabThera given by subcutaneous injection
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from two studies which showed that a fixed dose of MabThera (rituximab) can be administered subcutaneously (SC), potentially allowing patients to spend less time in infusion centers receiving their MabThera treatment.
Boehringer Ingelheim and Apexigen sign manufacturing agreement
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim Biopharmaceuticals, a global leader in the field of biopharmaceuticals manufacturing, and Apexigen, an emerging biopharmaceutical company dedicated to the discovery and development of best-in-class therapeutic monoclonal antibodies, announced the signing of a manufacturing supply agreement.
Roche and the Innovative Medicines Initiative join forces to promote use of Nobel Prize-winning stem cell technology
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and the Innovative Medicines Initiative (IMI) announced the launch of StemBANCC, a new academic–industry partnership that unites ten pharmaceutical companies and 23 academic institutions.
Novo Nordisk to create the world's first all-diabetes professional cycling team
- Details
- Category: Novo Nordisk
Novo Nordisk announced a unique partnership to form Team Novo Nordisk, a global sports team with more than 100 cyclists, triathletes and runners who all have diabetes, spearheaded by the world's first all-diabetes pro-cycling team.
More Pharma News ...
- GSK welcomes the publication of the 2012 Access to Medicines Index
- Sanofi ranks third on the Access to Medicine Foundation's 2012 ATM Index
- Novartis highlights key data in patients with hematologic diseases and breast cancer
- Novartis receives FDA approval for Flucelvax®
- Shire and Boston Children's Hospital enter into broad research collaboration
- Results from the positive phase III AVAglio study
- Bayer's "Perspective on Innovation 2012"